Dionex Corporation has entered into an Asset Purchase Agreement with ESA Biosciences, a wholly owned subsidiary of Magellan Biosciences, Inc., to purchase ESA Biosciences HPLC related products, HPLC clinical assays, laboratory services and assets.

 

This acquisition will add three category-leading HPLC detector families to the Dionex HPLC product portfolio. The Corona® Family of Universal Charged Aerosol Detectors (CAD) is the industry gold standard ‘universal’ HPLC detector targeting pharmaceutical and biopharmaceutical development, manufacturing and QA/QC processes. The CoulArray® and Coulochem® detectors are the leading electrochemical detectors on the market targeting neuroscience, clinical, and metabolomics research applications. Combined with Dionex expertise in electrochemistry detection for carbohydrates and glycobiology, this acquisition will position Dionex as the leading provider of comprehensive electrochemistry solutions for liquid chromatography.

 

This acquisition will enable Dionex to enhance our product and applications portfolio and meet the needs of customers in neuroscience, clinical diagnostic, biomedical research, and industrial laboratories worldwide – from pharmaceutical research and quality control, to food and beverage, and scientific discovery.

 

“We are very excited about the addition of the Life Sciences Tools Business Unit of ESA Biosciences, its product lines and services to our business,” says Dr. Frank Witney, President and CEO at Dionex Corporation. “We see excellent synergy with Dionex from a technology perspective, as well as both of our long histories of creating novel applications solutions to meet our customers’ needs,” says Dr. Jasmine Gruia-Gray, President at ESA Biosciences, Life Sciences Tools Business Unit.

 

Source: Dionex Corp.